TuHURA Biosciences (HURA) Financials

TuHURA Biosciences logo
$1.40 +0.00 (+0.21%)
As of 01:20 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Annual Income Statements for TuHURA Biosciences

Annual Income Statements for TuHURA Biosciences

This table shows TuHURA Biosciences' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 6/30/2015 6/30/2016 6/30/2017 6/30/2018 6/30/2019 6/30/2020 6/30/2021 6/30/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders
-4.35 9.10 8.87 11 -8.13 -9.14 -42 -25 -29 -23 -30
Consolidated Net Income / (Loss)
-4.35 8.86 8.08 11 -8.05 -9.13 -38 -23 -29 -22 -30
Net Income / (Loss) Continuing Operations
-4.35 -3.56 8.08 11 -8.31 -9.13 -38 -23 -29 -22 -30
Total Pre-Tax Income
-4.35 -3.56 8.08 11 -8.66 -9.13 -38 -23 -29 -22 -30
Total Operating Income
-4.72 -6.21 8.32 11 -8.40 -9.20 -38 -23 -30 -18 -32
Total Gross Profit
0.00 - 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue
0.00 - 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue
0.00 - 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses
4.72 6.21 -8.32 -11 8.40 9.20 38 23 30 18 32
Selling, General & Admin Expense
2.17 2.85 -3.32 -4.04 4.74 4.51 9.76 7.51 4.14 3.87 7.58
Research & Development Expense
2.56 3.36 -5.00 -7.13 3.66 3.63 28 15 26 13 21
Restructuring Charge
- - - - - - - - - 0.44 3.68
Total Other Income / (Expense), net
0.38 2.65 -0.24 -0.04 -0.26 0.07 -0.13 0.02 0.45 -4.03 1.93
Interest Expense
0.00 - - - - - - - 0.02 4.14 0.63
Interest & Investment Income
0.00 - - - - - - - 0.13 0.42 0.85
Other Income / (Expense), net
0.38 2.65 -0.24 -0.04 -0.26 0.07 -0.13 0.02 0.33 -0.31 1.70
Preferred Stock Dividends Declared
- -0.24 -0.79 -0.18 0.08 0.02 3.21 2.47 0.00 0.97 0.01
Basic Earnings per Share
$0.46 $0.83 $0.74 $5.42 $3.16 ($0.87) ($1.60) ($25.80) ($2.47) ($1.21) ($0.63)
Weighted Average Basic Shares Outstanding
9.52M 10.95M 12.05M 2.09M 2.57M 10.44M 25.89M 974K 11.89M 18.66M 47.93M
Diluted Earnings per Share
$0.46 $0.83 - - - - - - ($2.47) ($1.21) ($0.63)
Weighted Average Diluted Shares Outstanding
39.48M - 21.55M 22.41M 11.39M 23.54M 43.17M 80.81M 11.89M 18.66M 47.93M
Weighted Average Basic & Diluted Shares Outstanding
39.48M - 21.55M 22.41M 11.39M 23.54M 43.17M 80.81M 1.75M 43.68M 63.58M

Quarterly Income Statements for TuHURA Biosciences

This table shows TuHURA Biosciences' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 9/30/2023 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Income / (Loss) Attributable to Common Shareholders
-3.14 -5.27 -6.54 -16 -6.67 -9.53 -7.10 -6.76 -7.54 -9.23 -6.41
Consolidated Net Income / (Loss)
-2.96 -5.27 -5.58 -16 -6.66 -9.52 -7.10 -6.76 -7.54 -9.22 -6.41
Net Income / (Loss) Continuing Operations
-2.96 -5.27 -5.58 -16 -6.66 -9.49 -7.10 -6.58 -7.54 -9.22 -6.41
Total Pre-Tax Income
-2.96 -5.27 -5.58 -16 -6.66 -9.49 -7.10 -6.58 -7.54 -9.22 -6.41
Total Operating Income
-2.96 -3.62 -3.73 -12 -7.02 -9.88 -6.73 -8.17 -7.53 -8.76 -5.66
Total Gross Profit
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Revenue
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Cost of Revenue
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Operating Expenses
2.96 3.62 3.73 12 7.02 9.88 6.73 8.17 7.53 8.76 5.66
Selling, General & Admin Expense
1.10 0.80 0.78 0.81 2.02 1.86 1.59 -1.56 2.30 2.14 1.96
Research & Development Expense
1.86 2.82 2.95 11 4.58 4.93 4.97 6.06 5.23 6.62 3.70
Restructuring Charge
- - - - 0.42 3.09 0.17 - 0.00 0.00 0.00
Total Other Income / (Expense), net
0.00 -1.65 -1.85 -4.10 0.35 0.38 -0.37 1.60 -0.01 -0.46 -0.75
Interest Expense
- 1.36 2.00 - 0.00 0.00 0.02 0.61 0.03 0.47 0.75
Interest & Investment Income
- 0.06 0.13 - 0.10 0.03 0.14 0.14 0.02 0.01 0.00
Other Income / (Expense), net
0.00 -0.35 0.02 -0.33 0.25 0.35 -0.50 2.07 0.00 0.00 0.00
Preferred Stock Dividends Declared
0.18 0.00 0.97 0.79 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Basic Earnings per Share
($63.92) ($0.43) ($0.54) ($0.88) ($0.15) ($0.21) ($0.14) ($0.14) ($0.13) ($0.14) ($0.10)
Weighted Average Basic Shares Outstanding
49K 12.18M 12.18M 18.66M 43.40M 44.56M 50.67M 47.93M 60.01M 63.96M 65.00M
Diluted Earnings per Share
- ($0.43) ($0.54) ($0.88) ($0.15) ($0.21) ($0.14) ($0.14) ($0.13) ($0.14) ($0.10)
Weighted Average Diluted Shares Outstanding
3.39B 12.18M 12.18M 18.66M 43.40M 44.56M 50.67M 47.93M 60.01M 63.96M 65.00M
Weighted Average Basic & Diluted Shares Outstanding
3.39B 39.04B 55.30B 43.68M 43.68M 50.05M 51.26M 63.58M 63.68M 63.73M 65.76M

Annual Cash Flow Statements for TuHURA Biosciences

This table details how cash moves in and out of TuHURA Biosciences' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 6/30/2015 6/30/2016 6/30/2017 6/30/2018 6/30/2019 6/30/2020 6/30/2021 6/30/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents
-3.01 4.40 0.43 -0.61 -2.25 -1.33 8.15 1.24 -11 8.99 -9.04
Net Cash From Operating Activities
-3.85 13 -8.02 -9.85 -6.33 -7.93 -19 -20 -12 -15 -28
Net Cash From Continuing Operating Activities
-3.85 -5.15 -8.02 -9.85 -6.34 -7.93 -19 -20 -12 -15 -28
Net Income / (Loss) Continuing Operations
-4.35 8.86 -8.08 -11 -8.05 -9.13 -38 -23 -29 -22 -30
Consolidated Net Income / (Loss)
-4.35 -8.86 -8.08 -11 -8.05 -9.13 -38 -23 -29 -22 -30
Depreciation Expense
- - - - - 0.00 0.03 0.06 0.18 0.12 0.07
Amortization Expense
0.00 0.01 0.02 0.02 0.02 0.01 0.10 0.00 0.01 1.28 0.48
Non-Cash Adjustments To Reconcile Net Income
0.66 1.14 0.82 0.82 1.15 1.04 20 1.94 17 1.96 5.02
Changes in Operating Assets and Liabilities, net
-0.16 2.57 -0.77 0.45 0.54 0.15 -0.45 0.27 0.49 3.60 -3.15
Net Cash From Investing Activities
0.00 -0.02 -0.02 -0.01 0.00 0.00 0.96 0.00 -1.30 -6.05 -1.34
Net Cash From Continuing Investing Activities
0.00 -0.02 -0.02 -0.01 0.00 0.00 0.96 0.00 -1.30 -6.05 -1.34
Purchase of Property, Plant & Equipment
- - - - - 0.00 -0.01 0.00 -0.08 -0.06 -0.08
Acquisitions
- - - - - - - - -1.22 -5.99 -1.26
Net Cash From Financing Activities
0.85 9.57 8.47 9.25 4.07 6.60 26 22 2.66 30 20
Net Cash From Continuing Financing Activities
0.85 9.57 8.47 9.25 4.07 6.60 26 22 2.66 30 20
Repayment of Debt
-0.55 - - - - -0.03 -0.50 - 0.00 27 -2.33
Repurchase of Common Equity
- - - - - - - 0.00 -0.02 -0.30 -1.56
Payment of Dividends
-0.01 0.01 0.01 -0.01 -0.01 -0.01 -0.01 -0.01 0.00 -3.63 -0.51
Issuance of Debt
0.00 2.45 7.93 8.95 3.36 6.58 22 22 2.69 0.00 3.00
Issuance of Common Equity
- - - - - - - - 0.00 5.00 18
Other Financing Activities, net
1.40 0.58 0.55 0.31 0.72 0.05 4.48 0.07 0.00 1.25 3.02
Cash Interest Paid
- - - - - 0.00 0.03 - - 0.00 0.06

Quarterly Cash Flow Statements for TuHURA Biosciences

This table details how cash moves in and out of TuHURA Biosciences' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 9/30/2023 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Change in Cash & Equivalents
-1.32 9.97 7.28 4.18 -6.44 2.29 -5.82 0.92 2.68 -5.30 0.90
Net Cash From Operating Activities
-1.32 -7.58 -3.23 -8.99 -4.74 -6.25 -11 -5.56 -4.41 -8.63 -5.01
Net Cash From Continuing Operating Activities
-1.32 -7.58 -3.23 -8.99 -4.74 -6.25 -11 -5.56 -4.41 -8.63 -5.01
Net Income / (Loss) Continuing Operations
-2.96 -7.15 -5.58 -16 -6.66 -9.52 -7.10 -6.76 -7.54 -9.22 -6.41
Consolidated Net Income / (Loss)
-2.96 -7.15 -5.58 -16 -6.66 -9.52 -7.10 -6.76 -7.54 -9.22 -6.41
Depreciation Expense
0.02 0.05 0.03 0.08 0.01 0.01 0.02 0.02 0.02 0.03 0.03
Amortization Expense
- - 0.67 1.28 0.00 - - 0.48 0.00 0.30 0.38
Non-Cash Adjustments To Reconcile Net Income
1.32 -0.71 0.27 0.66 1.42 1.41 1.95 0.24 2.80 2.14 1.42
Changes in Operating Assets and Liabilities, net
0.31 -0.22 1.38 4.67 0.49 1.86 -5.95 0.46 0.30 -1.88 -0.43
Net Cash From Financing Activities
-0.00 18 16 19 -0.55 8.70 5.27 6.51 7.14 3.47 5.91
Net Cash From Continuing Financing Activities
-0.00 18 16 19 -0.55 8.70 5.27 6.51 7.14 3.47 5.91
Repayment of Debt
- - -0.02 - 0.00 - -0.53 -1.80 -0.20 -0.20 -0.02
Payment of Dividends
-0.00 0.00 - -3.62 -0.50 -0.00 -0.00 -0.00 -0.00 -0.00 -0.00
Issuance of Debt
- - 9.50 - 0.00 - - 3.00 0.00 3.60 5.60
Issuance of Common Equity
- - 5.00 -5.58 0.00 - 6.20 6.19 7.50 0.31 0.45
Other Financing Activities, net
- - 0.83 - -0.05 3.12 -0.72 0.67 -0.16 -0.24 -0.12
Cash Interest Paid
- - - - 0.00 - - 0.04 0.03 0.00 0.21

Annual Balance Sheets for TuHURA Biosciences

This table presents TuHURA Biosciences' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 6/30/2015 6/30/2016 6/30/2017 6/30/2018 6/30/2019 6/30/2020 6/30/2021 6/30/2022 6/30/2023 12/31/2024 12/31/2025
Total Assets
2.58 6.36 7.91 7.07 4.04 2.94 11 16 3.98 20 27
Total Current Assets
2.58 6.32 7.87 7.05 4.03 2.85 12 13 3.27 20 4.62
Cash & Equivalents
1.75 6.16 6.59 5.97 3.72 2.39 11 12 1.54 13 3.62
Other Current Assets
0.58 0.02 0.08 0.04 0.00 0.09 0.00 0.00 1.08 6.95 1.00
Plant, Property, & Equipment, net
0.00 0.00 0.00 0.00 0.00 0.00 0.15 0.09 0.71 0.12 0.30
Total Noncurrent Assets
0.00 0.04 0.04 0.03 0.01 0.09 0.00 2.60 0.00 0.23 22
Goodwill
- - - - - - - - - 0.00 11
Other Noncurrent Operating Assets
- - - - 0.00 0.09 0.00 2.60 0.00 0.23 12
Other Noncurrent Nonoperating Assets
- - - - - - - - - - 0.00
Total Liabilities & Shareholders' Equity
2.58 6.36 7.91 7.07 4.04 2.94 14 16 3.98 20 27
Total Liabilities
3.40 1.50 1.33 1.64 1.74 2.68 2.22 4.15 3.25 5.37 6.42
Total Current Liabilities
0.85 0.63 1.30 1.64 1.74 2.68 2.22 3.99 3.08 5.33 5.92
Short-Term Debt
- - - - - - - - - - 0.00
Accounts Payable
0.85 0.63 1.27 1.64 1.74 2.68 2.22 3.99 2.78 5.17 5.72
Other Current Liabilities
- 0.00 0.03 - - - - - 0.30 0.16 0.20
Total Noncurrent Liabilities
2.54 0.87 0.03 0.00 0.00 0.00 0.00 0.16 0.17 0.04 0.50
Long-Term Debt
- - - - - - - - - 0.00 0.00
Noncurrent Deferred & Payable Income Tax Liabilities
- - - - - - - - - 0.00 0.20
Other Noncurrent Operating Liabilities
2.54 0.87 0.03 0.00 - 0.00 - 0.16 0.17 0.04 0.30
Total Equity & Noncontrolling Interests
-0.82 4.86 6.58 5.44 1.97 0.26 11 12 0.73 15 21
Total Preferred & Common Equity
-0.82 4.86 6.58 5.44 6.67 0.26 11 12 0.73 15 21
Preferred Stock
- 6.57 6.43 6.43 4.98 4.80 15 13 11 0.28 0.28
Total Common Equity
-0.82 -1.71 0.15 -0.99 -3.01 -4.54 -4.35 -0.76 -9.91 14 21
Common Stock
17 29 37 43 51 65 107 136 141 125 162
Retained Earnings
-19 -32 -41 -52 -61 -70 -111 -136 -151 -111 -141

Quarterly Balance Sheets for TuHURA Biosciences

This table presents TuHURA Biosciences' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026 9/30/2026
Total Assets
1.48 1.89 7.45 15 35 26 30 32 36
Total Current Assets
0.78 1.19 6.76 14 13 3.50 6.98 1.66 3.68
Cash & Equivalents
0.22 0.66 6.35 6.22 8.51 2.70 6.30 1.00 1.89
Other Current Assets
0.00 0.22 0.20 8.11 4.03 0.81 0.68 0.66 1.79
Plant, Property, & Equipment, net
0.69 0.70 0.69 0.15 0.14 0.30 0.33 0.43 0.41
Total Noncurrent Assets
0.00 0.00 0.00 0.16 22 22 22 30 32
Goodwill
- - - - 14 14 11 11 11
Other Noncurrent Operating Assets
0.00 0.00 0.00 0.16 8.38 8.34 12 12 14
Other Noncurrent Nonoperating Assets
- - - - - - - 7.30 6.92
Total Liabilities & Shareholders' Equity
1.48 1.89 7.45 15 35 26 30 32 36
Total Liabilities
3.50 2.05 1.52 4.78 15 8.92 6.51 13 17
Total Current Liabilities
3.34 1.87 1.34 4.78 15 8.83 6.07 9.26 7.76
Short-Term Debt
- - - - 0.43 0.49 - 0.00 0.00
Accounts Payable
3.00 1.72 1.24 4.62 12 5.48 5.86 3.87 7.20
Other Current Liabilities
0.34 0.15 0.10 0.16 2.64 2.86 0.21 5.39 0.56
Total Noncurrent Liabilities
0.17 0.18 0.18 -3.06 0.00 0.08 0.45 3.99 9.53
Long-Term Debt
- - - - - - - 3.60 9.20
Noncurrent Deferred & Payable Income Tax Liabilities
- - - - - - 0.20 0.20 0.20
Other Noncurrent Operating Liabilities
0.17 0.18 0.18 -3.06 0.00 0.08 0.25 0.19 0.13
Total Equity & Noncontrolling Interests
-2.03 -0.16 5.92 13 19 17 23 19 19
Total Preferred & Common Equity
-2.03 -0.16 5.92 9.86 19 17 23 19 19
Preferred Stock
11 10 10 0.28 0.28 0.28 0.28 0.28 0.28
Total Common Equity
-13 -10 -4.33 13 19 16 23 18 19
Common Stock
142 145 153 130 146 151 172 176 183
Retained Earnings
-155 -156 -158 -118 -127 -134 -149 -158 -164

Annual Metrics And Ratios for TuHURA Biosciences

This table displays calculated financial ratios and metrics derived from TuHURA Biosciences' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 6/30/2015 6/30/2016 6/30/2017 6/30/2018 6/30/2019 6/30/2020 6/30/2021 6/30/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding
0.00 40,253,056.00 13,461,645.00 22,012,237.00 2,652,038.00 11,429,228.00 32,617,939.00 65,532,826.00 3,387,808,000.00 - 51,258,085.00
DEI Adjusted Shares Outstanding
0.00 16.00 22.00 36.00 43.00 187.00 533.00 1,070.00 2,765,558.00 - 51,258,085.00
DEI Earnings Per Adjusted Shares Outstanding
0.00 - 403,282.64 314,293.00 -189,038.42 -48,893.05 -77,868.67 -23,486.92 -10.60 - -0.59
Growth Metrics
- - - - - - - - - - -
Revenue Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth
31.71% 18.25% 327.94% 37.84% -177.46% -5.43% -318.74% 40.79% -29.41% 43.55% -78.29%
EBIT Growth
31.71% 18.01% 326.81% 37.82% -177.78% -5.35% -319.66% 40.83% -29.87% 39.16% -67.52%
NOPAT Growth
-189.93% -31.52% 233.90% 34.30% -152.61% -9.52% -314.94% 40.57% -31.23% 40.70% -80.15%
Net Income Growth
31.62% 303.89% 0.00% 37.82% -172.26% -13.39% -319.66% 40.83% -29.37% 26.04% -38.60%
EPS Growth
0.00% 80.43% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 51.01% 47.93%
Operating Cash Flow Growth
3.77% -33.55% -163.72% -22.84% 35.77% -25.30% -137.89% -8.12% 41.39% -23.24% -87.59%
Free Cash Flow Firm Growth
-239.64% 0.55% 193.84% 66.49% -142.41% -16.08% -377.84% 37.51% -16.34% 24.58% -149.30%
Invested Capital Growth
52.16% 49.59% 99.42% -7,066.52% -170.54% -46.60% 38.33% 101.14% -5,460.00% 340.90% 793.87%
Revenue Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth
-172.78% 18.17% 215.38% 131.67% -159.79% -7.38% -0.88% -5.98% -101.02% -101.27% 4.76%
EBIT Q/Q Growth
-172.78% 18.06% 216.63% 132.27% -159.99% -7.36% -0.97% -5.87% -75.60% -91.89% 3.72%
NOPAT Q/Q Growth
-3,523.92% -30.34% 0.00% 120.02% -140.70% -11.14% -0.78% -6.28% -76.07% -87.46% -2.70%
Net Income Q/Q Growth
-173.56% 303.69% 0.00% 131.98% -155.76% -15.73% -75.38% 39.57% -74.92% -132.37% 3.58%
EPS Q/Q Growth
360.00% -1.19% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -74.92% -476.19% -3.28%
Operating Cash Flow Q/Q Growth
4.10% -16.93% -169.09% 8.51% 10.22% -10.68% -12.60% -1.51% 22.14% -103.37% -11.98%
Free Cash Flow Firm Q/Q Growth
-460.11% -51.89% 1,031.49% 131.49% -134.26% -6.04% 3.95% -17.98% -66.42% -178.49% -2.61%
Invested Capital Q/Q Growth
-43.94% 20.09% 99.14% 36.64% -62.61% -69.93% -245.40% -97.26% -208.50% 551.47% 18.79%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent
100.00% -248.79% 100.00% 100.00% 92.90% 100.00% 100.00% 100.00% 100.00% 100.00% 100.62%
Interest Burden Percent
100.04% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 99.61% 121.09% 99.25%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)
504.78% 439.15% 141.32% 185.43% -217.44% -818.28% -706.34% -202.55% -468.10% -282.97% -169.18%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -114,702.67% 0.00% -779.40% -391.01%
Operating Return on Assets (OROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)
504.78% 439.15% -19.29% -12.92% 117.51% 2,770.23% 579.13% 46.25% 398.85% -81.27% -166.53%
Return on Equity Simple (ROE_SIMPLE)
529.25% 182.45% 122.85% 204.93% -120.72% -3,469.96% -361.95% -192.12% -4,010.51% -148.57% 0.00%
Net Operating Profit after Tax (NOPAT)
-3.31 -6.21 8.32 11 -5.88 -6.44 -27 -16 -21 -12 -22
NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)
-33.36% 381.18% -3.75% -0.58% -46.20% -92.48% -162.14% -57.31% -127.40% -131.45% -95.78%
Return On Investment Capital (ROIC_SIMPLE)
- - - - - - - - -2,850.25% -84.66% -106.33%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)
-4.35 -3.56 8.08 11 -8.66 -9.13 -38 -23 -29 -18 -30
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-4.35 -3.55 8.10 11 -8.65 -9.12 -38 -23 -29 -17 -30
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
0.00 0.00 100,667.37 0.00 0.00 0.00 0.00 0.00 0.00 0.48 0.06
Price to Tangible Book Value (P/TBV)
0.00 0.00 136,616.18 0.00 0.00 0.00 0.00 0.00 0.00 0.48 0.13
Price to Revenue (P/Rev)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)
0.00 0.00 1,737.29 664.38 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.06% 0.15% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 60,778.69 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 1,903.26 673.45 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 1,907.19 674.93 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 1,852.39 672.74 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 2,192.57 642.32 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage
3.62 -1.96 -1.11 -1.05 -1.27 -2.61 -1.32 -1.06 -1.06 -0.93 -0.46
Leverage Ratio
-4.40 2.21 1.25 1.25 1.50 3.13 1.33 1.22 1.59 1.56 1.33
Compound Leverage Factor
-4.40 2.21 1.25 1.25 1.50 3.13 1.33 1.22 1.58 1.89 1.32
Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 97.67% 118.22% 253.00% 1,826.62% 141.11% 106.43% 1,456.22% 1.91% 1.33%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
100.00% 100.00% 2.33% -18.22% -153.00% -1,726.62% -41.11% -6.43% -1,356.22% 98.09% 98.67%
Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score
2,755.52 0.00 6,937.56 2,746.54 31.42 44.76 977.38 115.64 -13.32 -9.13 -10.80
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 113.65% 106.97% 154.04% 438.54% 181.99% 122.83% 185.21% 71.28% 1.57%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
3.02 10.07 6.03 4.30 2.31 1.07 5.31 3.32 1.06 3.68 0.78
Quick Ratio
2.06 9.81 5.05 3.64 2.13 0.89 4.75 2.95 0.50 2.37 0.61
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-6.12 -7.49 7.03 12 -4.96 -5.76 -28 -17 -20 -15 -38
Operating Cash Flow to CapEx
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -377,200.00% 0.00% -15,084.89% -25,434.56% -36,314.49%
Free Cash Flow to Firm to Interest Expense
-2,924.80 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -1,071.08 -3.65 -60.19
Operating Cash Flow to Interest Expense
-1,842.69 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -639.49 -3.56 -44.19
Operating Cash Flow Less CapEx to Interest Expense
-1,842.69 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -643.73 -3.57 -44.31
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
-2.58 -1.30 -0.01 -0.54 -1.45 -2.13 -1.31 0.02 -0.80 1.94 17
Invested Capital Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital
2.81 1.28 1.29 -0.53 -0.92 -0.68 0.82 1.33 -0.82 2.74 15
Enterprise Value (EV)
15,683 0.00 15,413 7,518 172 395 3,707 912 357 -5.53 -2.07
Market Capitalization
15,685 0.00 15,414 7,517 171 393 3,702 911 348 6.85 1.27
Book Value per Share
($0.09) $0.00 $0.01 ($0.05) ($1.14) ($0.40) ($0.13) ($0.01) $0.00 $0.00 $0.40
Tangible Book Value per Share
($0.09) $0.00 $0.01 ($0.05) ($1.14) ($0.40) ($0.13) ($0.01) $0.00 $0.00 $0.19
Total Capital
-0.82 4.86 6.58 5.44 1.97 0.26 11 12 0.73 15 21
Total Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt
-1.75 -6.16 -6.59 -5.97 -3.72 -2.39 -11 -12 -1.54 -13 -3.62
Capital Expenditures (CapEx)
0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.08 0.06 0.08
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-0.03 -0.46 -0.02 -0.56 -1.44 -2.22 -0.96 -2.51 -1.35 1.62 -4.92
Debt-free Net Working Capital (DFNWC)
1.72 5.69 6.57 5.41 2.28 0.18 9.57 9.27 0.19 14 -1.30
Net Working Capital (NWC)
1.72 5.69 6.57 5.41 2.28 0.18 9.57 9.27 0.19 14 -1.30
Net Nonoperating Expense (NNE)
1.04 -15 0.24 0.04 2.17 2.69 12 6.78 8.48 9.33 7.79
Net Nonoperating Obligations (NNO)
-1.75 -6.16 -6.59 -5.97 -3.42 -2.39 -12 -12 -1.54 -13 -3.62
Total Depreciation and Amortization (D&A)
0.00 0.01 0.02 0.02 0.02 0.01 0.13 0.06 0.18 1.40 0.55
Debt-free, Cash-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
$65.00 $8.30 $370.00 $270.00 $158.00 $43.50 ($80.00) ($26.00) ($11,355.75) ($392.00) ($0.63)
Adjusted Weighted Average Basic Shares Outstanding
76.14K 1.09M 24.09K 41.72K 51.49K 208.88K 517.72K 974.04K 1.32K 21.51K 47.93M
Adjusted Diluted Earnings per Share
$65.00 $8.30 $370.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 ($0.63)
Adjusted Weighted Average Diluted Shares Outstanding
76.14K 0.00 43.10K 44.82K 227.77K 470.88K 863.50K 1.62M 1.43K 0.00 47.93M
Adjusted Basic & Diluted Earnings per Share
$65.00 $8.30 $370.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
78.96K 0.00 43.10K 44.82K 227.77K 470.88K 863.50K 1.62M 1.43K 0.00 63.58M
Normalized Net Operating Profit after Tax (NOPAT)
-3.31 -4.35 5.82 7.82 -5.88 -6.44 -27 -16 -21 -12 -20
Normalized NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
-2,078.45 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -1,574.82 -4.33 -48.12
NOPAT to Interest Expense
-1,581.66 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -1,114.90 -2.99 -35.60
EBIT Less CapEx to Interest Expense
-2,078.45 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -1,579.06 -4.34 -48.25
NOPAT Less CapEx to Interest Expense
-1,581.66 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -1,119.14 -3.00 -35.72
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
-0.14% -0.09% -0.10% 0.08% -0.10% -0.09% -0.02% -0.04% 0.00% -16.74% -1.69%
Augmented Payout Ratio
-0.14% -0.09% -0.10% 0.08% -0.10% -0.09% -0.02% -0.04% -0.08% -18.12% -6.87%

Quarterly Metrics And Ratios for TuHURA Biosciences

This table displays calculated financial ratios and metrics derived from TuHURA Biosciences' official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 9/30/2023 6/30/2024 9/30/2024 12/31/2024 9/30/2024 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
DEI Shares Outstanding
1,746,408.00 55,304,613,000.00 55,304,613,000.00 - - 43,680,396.00 50,046,926.00 51,258,085.00 63,578,528.00 63,682,528.00 63,726,617.00
DEI Adjusted Shares Outstanding
1,426.00 45,146,623.00 45,146,623.00 - - 43,680,396.00 50,046,926.00 51,258,085.00 63,578,528.00 63,682,528.00 63,726,617.00
DEI Earnings Per Adjusted Shares Outstanding
-2,199.86 -0.12 -0.15 - - -0.22 -0.14 -0.13 -0.12 -0.14 -0.10
Growth Metrics
- - - - - - - - - - -
Revenue Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth
35.67% -65.44% -38.50% 47.58% 27.25% -152.18% -134.83% 21.51% -11.20% 11.26% 27.12%
EBIT Growth
35.55% -14.82% -13.63% 34.26% 27.04% -149.03% -91.21% 16.65% -11.32% 7.99% 21.71%
NOPAT Growth
36.25% -3.42% -12.97% 36.76% 25.42% -172.91% -80.41% -11.38% -7.31% 11.27% 15.88%
Net Income Growth
35.55% -52.44% -70.93% 12.87% 27.04% -80.88% -27.30% 14.15% -13.09% 3.16% 9.76%
EPS Growth
0.00% 0.00% 0.00% 40.54% 0.00% 51.16% 74.07% 65.85% 13.33% 33.33% 28.57%
Operating Cash Flow Growth
79.32% -250.90% -76.71% -464.30% -43.43% 17.60% -243.40% -113.72% 6.87% -38.18% 54.84%
Free Cash Flow Firm Growth
146.70% 100.31% 42.48% 9.62% -191.18% -148,285.66% -1,267.90% -167.80% -11.70% 55.14% 55.72%
Invested Capital Growth
-188.51% -147.68% -157.89% 340.90% 40.90% 1,483.30% 3,497.19% 793.87% 152.32% 21.42% 32.71%
Revenue Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth
-31.27% -32.71% 23.01% -426.83% 7.07% -40.83% 28.31% 20.76% -33.98% -12.44% 37.75%
EBIT Q/Q Growth
11.18% -33.89% 6.48% -492.22% 7.01% -40.74% 28.19% 13.90% -23.31% -16.38% 35.40%
NOPAT Q/Q Growth
11.56% -22.17% -3.08% -455.56% 7.38% -40.74% 31.86% -21.45% 7.87% -16.38% 35.40%
Net Income Q/Q Growth
11.18% -77.76% -5.96% -680.03% 7.01% -42.91% 25.42% 4.80% -11.47% -22.38% 30.51%
EPS Q/Q Growth
0.00% 0.00% -5.96% 0.00% 0.00% -40.00% 33.33% 0.00% 7.14% -7.69% 28.57%
Operating Cash Flow Q/Q Growth
12.67% -475.78% 57.43% -291.05% -31.00% -31.86% -77.44% 49.89% 20.57% -95.64% 42.00%
Free Cash Flow Firm Q/Q Growth
277.12% -99.52% -11,277.67% -3,647.58% -86.40% -37.96% -3.18% -7.02% 26.68% 44.59% -1.86%
Invested Capital Q/Q Growth
-178.86% 63.34% 47.81% 551.47% -15.02% 69.85% 28.17% 18.79% -2.43% -18.26% 40.08%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 102.81% 100.00% 100.00% 100.00%
Interest Burden Percent
100.00% 132.77% 150.42% 131.71% 100.00% 96.43% 100.15% 107.69% 100.09% 105.25% 113.23%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)
-342.86% -916.82% -655.32% -282.97% 4,543.20% -307.41% -274.60% -169.18% -171.31% -161.39% -167.53%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% -779.40% 0.00% -279.37% -251.65% -391.01% -278.24% -192.82% -152.48%
Operating Return on Assets (OROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)
703.15% 2,079.59% 755.29% -81.27% 153,974.76% -139.56% -147.21% -166.53% -168.66% -159.02% -164.92%
Return on Equity Simple (ROE_SIMPLE)
642.40% 0.00% 0.00% 0.00% -443.60% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-2.07 -2.53 -2.61 -8.11 -1.55 -6.91 -4.71 -5.72 -5.27 -6.13 -3.96
NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)
-24.34% -98.78% -63.17% -106.79% -37.99% -59.76% -55.91% -12.78% -36.20% -48.37% -269.41%
Return On Investment Capital (ROIC_SIMPLE)
- 1,544.58% -44.09% -55.56% - -34.77% -27.27% -27.33% -22.73% -27.76% -14.07%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)
-2.96 -3.97 -3.71 -12 -2.16 -9.88 -7.09 -6.11 -7.53 -8.76 -5.66
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-2.95 -3.91 -3.01 -11 -2.14 -9.86 -7.07 -5.60 -7.51 -8.44 -5.25
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
0.00 0.00 0.00 0.48 282.62 0.19 0.25 0.06 0.13 0.22 7.31
Price to Tangible Book Value (P/TBV)
0.00 0.00 0.00 0.48 282.62 0.67 1.41 0.13 0.25 0.52 17.20
Price to Revenue (P/Rev)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 0.00 0.00 0.15 0.00 0.00 0.49 7.45
Enterprise Value to Revenue (EV/Rev)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.02 0.03 0.00 0.00 0.19 0.49
Long-Term Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.19 0.49
Financial Leverage
-0.96 -0.86 -0.97 -0.93 9.78 -0.45 -0.38 -0.46 -0.35 -0.34 -0.05
Leverage Ratio
1.93 1.83 1.46 1.56 -16.97 1.89 1.46 1.33 1.23 1.75 1.73
Compound Leverage Factor
1.93 2.44 2.20 2.06 -16.97 1.83 1.46 1.43 1.23 1.84 1.96
Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 2.18% 2.86% 0.00% 0.00% 16.29% 32.68%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 2.18% 2.86% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 16.29% 32.68%
Preferred Equity to Total Capital
-523.59% -6,251.22% 173.12% 1.91% 16.46% 1.40% 1.61% 1.33% 1.20% 1.26% 0.99%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
623.59% 6,351.22% -73.12% 98.09% 83.54% 96.42% 95.53% 98.67% 98.80% 82.45% 66.33%
Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 -0.02 -0.02 0.00 0.00 -0.12 -0.34
Net Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.30 0.07 0.00 0.00 -0.09 -0.27
Long-Term Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.12 -0.34
Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 -0.02 -0.02 0.00 0.00 -0.16 -0.44
Net Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.41 0.10 0.00 0.00 -0.12 -0.35
Long-Term Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.16 -0.44
Altman Z-Score
1,264.96 39.42 127.16 -8.14 42.04 -6.03 -8.20 -7.90 -7.53 -7.99 -2.26
Noncontrolling Interest Sharing Ratio
305.08% 326.83% 215.26% 71.28% -3,289.12% 54.60% 46.39% 1.57% 1.54% 1.47% 1.56%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
0.23 0.63 5.04 3.68 1.54 0.83 0.40 0.78 1.15 0.18 0.48
Quick Ratio
0.06 0.35 4.74 2.37 1.34 0.56 0.31 0.61 1.04 0.11 0.24
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
2.70 0.01 -1.44 -11 -2.46 -19 -20 -21 -15 -8.57 -8.73
Operating Cash Flow to CapEx
0.00% 0.00% 0.00% -23,727.48% 0.00% -112,356.81% 0.00% -19,949.81% -9,034.42% -6,302.91% 0.00%
Free Cash Flow to Firm to Interest Expense
0.00 0.01 -0.72 0.00 0.00 0.00 -1,192.45 -34.66 -552.95 -18.33 -11.60
Operating Cash Flow to Interest Expense
0.00 -5.59 -1.61 0.00 0.00 0.00 -670.61 -9.13 -157.75 -18.46 -6.65
Operating Cash Flow Less CapEx to Interest Expense
0.00 -5.59 -1.61 0.00 0.00 0.00 -670.61 -9.17 -159.50 -18.76 -6.65
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
-2.24 -0.82 -0.43 1.94 -1.33 11 15 17 17 14 19
Invested Capital Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital
-4.78 -2.55 -1.17 2.74 0.92 12 15 15 10 2.44 4.77
Enterprise Value (EV)
8,301 564 404 -5.53 397 -4.06 2.23 -2.07 -3.02 6.80 144
Market Capitalization
8,291 554 400 6.85 400 3.74 4.15 1.27 3.00 3.92 136
Book Value per Share
($7.23) $0.00 $0.00 $0.00 $0.00 $0.44 $0.33 $0.40 $0.45 $0.29 $0.29
Tangible Book Value per Share
($7.23) $0.00 $0.00 $0.00 $0.00 $0.13 $0.06 $0.19 $0.24 $0.12 $0.12
Total Capital
-2.03 -0.16 5.92 15 1.70 20 17 21 23 22 28
Total Debt
0.00 0.00 0.00 0.00 0.00 0.43 0.49 0.00 0.00 3.60 9.20
Total Long-Term Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 3.60 9.20
Net Debt
-0.22 -0.66 -6.35 -13 -3.02 -8.08 -2.20 -3.62 -6.30 2.60 7.31
Capital Expenditures (CapEx)
0.00 0.00 0.00 0.04 0.00 0.01 0.00 0.03 0.05 0.14 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-2.77 -1.34 -0.94 1.62 -1.79 -11 -7.53 -4.92 -5.38 -8.60 -5.97
Debt-free Net Working Capital (DFNWC)
-2.55 -0.68 5.41 14 1.23 -2.20 -4.84 -1.30 0.92 -7.60 -4.07
Net Working Capital (NWC)
-2.55 -0.68 5.41 14 1.23 -2.63 -5.33 -1.30 0.92 -7.60 -4.07
Net Nonoperating Expense (NNE)
0.89 2.73 2.97 7.58 0.61 2.61 2.39 1.04 2.27 3.09 2.45
Net Nonoperating Obligations (NNO)
-0.22 -0.66 -6.35 -13 -3.02 -8.08 -2.20 -3.62 -6.30 -4.69 0.39
Total Depreciation and Amortization (D&A)
0.02 0.05 0.70 1.36 0.02 0.01 0.02 0.50 0.02 0.32 0.41
Debt-free, Cash-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($2,241.75) ($294.00) ($61.25) ($0.88) ($1.37) ($0.21) ($0.14) ($0.14) ($0.13) ($0.14) ($0.10)
Adjusted Weighted Average Basic Shares Outstanding
1.40K 3.54K 36.38K 18.66M 1.59M 44.56M 50.67M 47.93M 60.01M 63.96M 65.00M
Adjusted Diluted Earnings per Share
$0.00 $0.00 $0.00 ($0.88) $0.00 ($0.21) ($0.14) ($0.14) ($0.13) ($0.14) ($0.10)
Adjusted Weighted Average Diluted Shares Outstanding
2.77M 31.87M 45.15M 18.66M 42.28B 44.56M 50.67M 47.93M 60.01M 63.96M 65.00M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 ($0.88) $0.00 $0.00 $0.00 ($0.14) $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
2.77M 31.87M 45.15M 43.68M 42.28B 50.05M 51.26M 63.58M 63.68M 63.73M 65.76M
Normalized Net Operating Profit after Tax (NOPAT)
-2.07 -2.53 -2.61 -8.11 -1.55 -6.91 -4.71 -5.72 -5.27 -6.13 -3.96
Normalized NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
0.00 -2.92 -1.85 0.00 0.00 0.00 -428.99 -10.03 -269.17 -18.74 -7.52
NOPAT to Interest Expense
0.00 -1.87 -1.30 0.00 0.00 0.00 -284.95 -9.40 -188.42 -13.12 -5.27
EBIT Less CapEx to Interest Expense
0.00 -2.92 -1.85 0.00 0.00 0.00 -428.99 -10.08 -270.92 -19.03 -7.52
NOPAT Less CapEx to Interest Expense
0.00 -1.87 -1.30 0.00 0.00 0.00 -284.95 -9.44 -190.17 -13.41 -5.27
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
-0.06% 0.01% 0.02% -16.74% -0.05% -13.95% -13.27% -1.69% -0.03% -0.03% -0.03%
Augmented Payout Ratio
-0.06% 0.01% 0.02% -18.12% -0.05% -14.75% -13.27% -6.87% -0.03% -0.03% -0.03%

Financials Breakdown Chart

Key Financial Trends

TuHURA Biosciences (NASDAQ:HURA) remains a development-stage biotechnology company with no reported revenue. The company has generated quarterly operating losses throughout the periods provided, while research and development spending continues to represent the majority of expenses. In Q2 2026, revenue was $0 and net loss attributable to common shareholders was $9.2 million, compared with a $7.5 million loss in Q1 2026 and a $9.5 million loss in Q2 2025.

There was some year-over-year improvement in reported operating expenses. Q2 2026 operating expenses declined to $8.8 million from $9.9 million in the restated Q2 2025 period, primarily because the prior-year quarter included a $3.1 million restructuring charge. However, underlying spending remains elevated: research and development expense increased to $6.6 million from $4.9 million, while selling, general and administrative expense rose to $2.1 million from $1.9 million.

Cash consumption is the primary financial concern. TuHURA used $8.6 million in operating cash during Q2 2026, up from $4.4 million in Q1 and $6.2 million in the restated Q2 2025 period. After financing and investing activity, cash and equivalents fell from $6.3 million at March 31, 2026, to just $1.0 million at June 30, 2026. The company raised $3.6 million through debt issuance during the quarter, but that was not enough to offset operating cash burn.

The balance sheet has also become more leveraged and less liquid. Total current assets were $1.7 million versus $9.3 million of current liabilities, implying a current ratio of approximately 0.18. TuHURA reported $3.6 million of long-term debt at quarter-end, compared with no short-term debt. The company’s $18.5 million of total equity provides some balance-sheet support, but retained earnings were negative $157.9 million, reflecting substantial cumulative losses.

Equity financing has helped fund operations, but it has also increased dilution risk. Weighted-average basic shares outstanding rose from 43.4 million in Q1 2025 to 64.0 million in Q2 2026. This growth suggests that future capital raises could further dilute existing shareholders if the company continues to operate without product revenue or positive cash flow.

  • Q2 2026 operating expenses were approximately 11% lower than the restated Q2 2025 level, although the comparison benefits from a prior-year restructuring charge.
  • Research and development investment remains substantial, reaching $6.6 million in Q2 2026 and indicating continued support for the company’s clinical and development programs.
  • TuHURA has demonstrated access to external capital markets, raising $7.5 million through common equity in Q1 2026 and $3.6 million through debt issuance in Q2 2026.
  • Total assets increased to $31.7 million at June 30, 2026, from $29.7 million at the end of Q1, supported partly by the addition of $7.3 million in other noncurrent nonoperating assets.
  • The company reported no revenue in each of the recent income statement periods provided, so financial performance remains tied primarily to clinical progress and future financing rather than commercial sales.
  • Goodwill and other noncurrent operating assets account for a large portion of total assets, making asset quality and potential future impairments important items for investors to monitor.
  • Operating cash outflow increased to $8.6 million in Q2 2026 from $4.4 million in Q1, while cash and equivalents plunged approximately 84% to $1.0 million.
  • Current liabilities of $9.3 million substantially exceeded current assets of $1.7 million, indicating significant near-term liquidity pressure.
  • The company recorded a $9.2 million net loss attributable to common shareholders in Q2 2026, and quarterly losses have remained broadly between approximately $6.6 million and $9.5 million across the periods provided.
  • Share dilution and financing risk are significant: weighted-average basic shares increased by roughly 47% from Q1 2025 to Q2 2026, while TuHURA also added $3.6 million of long-term debt.
11/18/26 01:20 PM ETAI Generated. May Contain Errors.

TuHURA Biosciences Financials - Frequently Asked Questions

According to the most recent income statement we have on file, TuHURA Biosciences' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

TuHURA Biosciences' net income appears to be on a downward trend, with a most recent value of -$30.05 million in 2025, falling from -$4.35 million in 2015. The previous period was -$21.68 million in 2024. Find out what analysts predict for TuHURA Biosciences in the coming months.

TuHURA Biosciences' total operating income in 2025 was -$31.80 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $31.80 million

Over the last 10 years, TuHURA Biosciences' total revenue changed from $0.00 in 2015 to $0.00 in 2025, a change of 0.0%.

In the past 10 quarters, TuHURA Biosciences' cash and equivalents has ranged from $216 thousand in Q1 2024 to $8.51 million in Q2 2025, and is currently $1.89 million as of their latest financial filing in Q3 2026.

TuHURA Biosciences had total debt of $0.00 at the end of 2025, compared with none in 2024, and none in 2015.

Over the last 10 years, TuHURA Biosciences' book value per share changed from -0.09 in 2015 to 0.40 in 2025.



Financial statements for NASDAQ:HURA last updated on 11/13/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners